Initial clinical evaluation of indigenous (90)Y-DOTATATE in sequential duo-PRRT approach ((177)Lu-DOTATATE and (90)Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, (90)Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

(177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy (Eβmax 0.497 MeV) and a shorter particle penetr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:World J Nucl Med
Egile Nagusiak: Parghane, Rahul V., Mitra, Arpit, Bannore, Trupti Upadhye, Rakshit, Sutapa, Banerjee, Sharmila, Basu, Sandip
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer - Medknow 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034792/
https://ncbi.nlm.nih.gov/pubmed/33850492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/wjnm.WJNM_52_20
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak